HAMANOVÁ, Markéta, Lenka ZDRAŽILOVÁ DUBSKÁ, Dalibor VALÍK and Jindřich LOKAJ. Přirozené protilátky proti alfa(1,3) galaktosylovému epitopu v séru nemocných s maligními nádory (Natural antibodies against alpha(1,3) galactosyl epitope in the serum of cancer patients). Epidemiologie, mikrobiologie, imunologie. Praha: Česká lékařská společnost Jana Evangelisty Purkyně, 2014, vol. 63, No 2, p. 130-133. ISSN 1210-7913.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Přirozené protilátky proti alfa(1,3) galaktosylovému epitopu v séru nemocných s maligními nádory
Name (in English) Natural antibodies against alpha(1,3) galactosyl epitope in the serum of cancer patients
Authors HAMANOVÁ, Markéta (203 Czech Republic), Lenka ZDRAŽILOVÁ DUBSKÁ (203 Czech Republic), Dalibor VALÍK (203 Czech Republic) and Jindřich LOKAJ (203 Czech Republic, guarantor, belonging to the institution).
Edition Epidemiologie, mikrobiologie, imunologie, Praha, Česká lékařská společnost Jana Evangelisty Purkyně, 2014, 1210-7913.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30300 3.3 Health sciences
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 0.353
RIV identification code RIV/00216224:14110/14:00076052
Organization unit Faculty of Medicine
UT WoS 000343635300012
Keywords in English alpha(1 3) galactosyl epitope; natural antibodies; anti-Gal; ELISA; cancer immunotherapy
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 6/2/2015 16:15.
Abstract
Východisko: Přirozené protilátky proti sacharidovým antigenům jsou součástí lidských sér; nejvíc je jich namířeno proti alfa-galaktosylovému epitopu (Galalfa1-3Galbeta1-4GlcNAc-R). Experimentální a úvodní klinické studie ukazují na možnost využití antigalaktosylových protilátek pro imunoterapii onkologických pacientů preparáty glykolipidů obsahujících alfa-galaktosylový epitop. Předpokladem tohoto terapeutického postupu je přítomnost dostatečného množství těchto protilátek v sérech nemocných s maligními nádory. V literatuře jsou zmínky o výskytu těchto protilátek u onkologických pacientů pouze ojedinělé. Údaje o jejich množství a o izotypové charakteristice u různých nádorových onemocnění chybí.
Abstract (in English)
Background: Natural antibodies against saccharide antigens are found in the human serum; most of them are directed against alpha-galactosyl epitope (Gal alpha 1-3Gal beta 1-4GlcNAc-R). Experimental and initial clinical studies show the potential for use of anti-galactosyl antibodies in the immunotherapy of cancer patients with glycolipids containing the alpha-galactosyl epitope. This therapeutic approach is based on the presence of these antibodies in the serum of cancer patients. Only scarce literature data is available on the incidence of these antibodies in cancer patients. Data is lacking on their amounts and isotype characteristics in different types of cancer. Material and methods: An ELISA test with a polyacrylamide-conjugated synthetic disaccharide, Gal alpha 1-3Gal beta, has been designed for quantitative detection of anti-galactosyl IgM, IgG, and IgA antibody isotypes. This test was used to screen the sera from 57 patients with breast, colorectal, or panceatic cancer or malignant melanoma and from 145 healthy controls. Results: The serum concentration of anti-galactosyl antibodies (anti-Gal) is gender dependent: anti-Gal IgM antibodies are present in higher titres in healthy women than in healthy men (p<0.01). Patients with breast, colorectal, or pancreatic cancer or malignant melanoma had comparable serum levels of anti-Gal IgM, IgG, and IgA antibody isotypes to healthy controls. Male patients with colorectal cancer had higher anti-Gal IgA antibodies than healthy men (p<0.01). Conclusion: Comparable concentrations and isotypes of anti-galactosyl antibodies are found in the serum of cancer patients and healthy controls.
Links
LM2011017, research and development projectName: Advanced Cell Immunotherapy Unit - ACIU
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 24/6/2024 13:21